Volitionrx Ltd: management transactions · United States · SEC (Form 4)

About Volitionrx Ltd

VolitionRx Ltd (ticker: VNRX) is a U.S.-listed healthcare company trading on NYSE American in the United States, focused on epigenetics-based diagnostics. Founded in 2010, the company began with a small laboratory footprint at the University of Namur in Belgium and has since evolved into an international organization with a purpose-built manufacturing facility in Belgium, an innovation laboratory in the U.S., and offices in California, London, Singapore, and Henderson, Nevada. Its corporate presence and investor relations base are in the United States, while research and development remain centered in Belgium. ([volition.com](https://volition.com/our-company/?utm_source=openai)) Volition’s business model is built around its proprietary Nucleosomics™ technology and its Nu.Q® biomarker platform. The company is developing and commercializing blood-based tests intended to help detect, monitor, and potentially stratify a range of diseases, including several cancers and conditions associated with NETosis, such as sepsis. A meaningful aspect of the portfolio is the extension into veterinary diagnostics, particularly the Nu.Q® Vet franchise, including feline cancer testing. This gives Volition exposure to both human and animal health markets, although it remains largely in a development and early commercialization phase rather than a fully scaled diagnostics supplier. ([ir.volition.com](https://ir.volition.com/)) From a competitive standpoint, Volition operates in a highly specialized niche at the intersection of diagnostic testing, oncology, inflammatory disease detection, and epigenetic biomarkers. Its differentiation lies in the scientific promise of Nu.Q® and the breadth of possible use cases across cancer screening, disease monitoring, trauma, sepsis, and veterinary oncology. That said, the company faces major execution hurdles typical of emerging diagnostics names: regulatory approval, reimbursement adoption, clinical validation, commercialization scale-up, and competition from much larger global diagnostic companies with greater capital resources. ([ir.volition.com](https://ir.volition.com/news-events/press-releases/detail/870/volitionrx-limited-announces-the-preparation-of-reimbursement-submission-for-its-nu-q-cancer-assays?utm_source=openai)) Recent developments suggest a company pushing to convert clinical momentum into commercial traction. In 2026, Volition reported first-quarter results and a business update, advanced reimbursement preparation in France for its Nu.Q® Cancer assays, announced breakthrough finger-prick detection of nucleosomes for sepsis applications, released Mayo Clinic-related trauma data, and submitted a manuscript for its Nu.Q® Vet Feline cancer test. The company also secured funding in January 2026 and later obtained EUR 2.0 million of non-dilutive funding from regional government agencies in Belgium, reinforcing its reliance on a mixed financing approach to support clinical studies, product commercialization, and general corporate needs. ([ir.volition.com](https://ir.volition.com/news-events/press-releases/detail/888/volitionrx-limited-announces-first-quarter-2026-financial-results-and-business-update?utm_source=openai))